RT Journal Article
SR Electronic
T1 Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.22.21262186
DO 10.1101/2021.08.22.21262186
A1 Gonzalez Lopez Ledesma, María M.
A1 Sanchez, Lautaro
A1 Ojeda, Diego S.
A1 Rouco, Santiago Oviedo
A1 Rossi, Andres H.
A1 Varese, Augusto
A1 Mazzitelli, Ignacio
A1 Pascuale, Carla A.
A1 Miglietta, Esteban A.
A1 Rodríguez, Pamela E.
A1 Pallarés, Horacio M.
A1 Costa Navarro, Guadalupe S.
A1 Caramelo, Julio J.
A1 Rothlauf, Paul W
A1 Liu, Zhuoming
A1 Bloyet, Louis-Marie
A1 Pontelli, Marjorie Cornejo
A1 Rasetto, Natali B.
A1 Wenker, Shirley D.
A1 Ramis, Lila Y.
A1 Bialer, Magalí G.
A1 Jose de Leone, María
A1 Hernando, C. Esteban
A1 Bianchimano, Luciana
A1 Rios, Antonella
A1 Treffinger Cienfuegos, María Soledad
A1 Rodriguez García, Diana R.
A1 Longueira, Yesica
A1 Laufer, Natalia
A1 Alvarez, Diego
A1 Ceballos, Ana
A1 Ochoa, Valeria
A1 Monzani, Cecilia
A1 Turk, Gariela
A1 Salvatori, Melina
A1 Carradori, Jorge
A1 Prost, Katherine
A1 Rima, Alejandra
A1 Varela, Claudia
A1 Ercole, Regina
A1 Toro, Rosana I.
A1 Gutierrez, Sebastian
A1 Zubieta, Martín
A1 Acuña, Dolores
A1 Nabaes Jodar, Mercedes S.
A1 Torres, Carolina
A1 Mojsiejczuk, Laura
A1 Viegas, Mariana
A1 Velazquez, Pilar
A1 Testa, Clarisa
A1 Kreplak, Nicolas
A1 Yanovsky, Marcelo
A1 Whelan, Sean
A1 Geffner, Jorge
A1 Pifano, Marina
A1 Gamarnik, Andrea V.
YR 2021
UL http://medrxiv.org/content/early/2021/10/25/2021.08.22.21262186.abstract
AB Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a local variant of interest (VOI: Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. A collection of 472 serum samples obtained between January and September 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity to the first-wave linages of SARS-CoV-2 and VOC are maintained within four months of vaccination. In addition, an improved antibody cross-neutralizing ability to circulating variants of concern (Beta, Gamma and Delta) was observed over time of vaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least four month and show a reduction of VOC escape over time of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH (NIAID) R01.AI095175 and PICT-2017-1717, PICT- 2015-2555 to AVG and by the National Ministry of Science Technology and Innovation or Argentina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the central ethics committee of Buenos Aires province, Argentina. File number: IF-2021-09238265-GDEBA-CECMSALGP. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available.